A group of German investigators demonstrated that the early increase in phosphorylated CREB (pCREB) is related to treatment response and does not depend on pharmacological interventions or brain-derived neurotrophic factor (BDNF) plasma levels. For the first time, cellular biological markers could be associated with response to psychotherapy. The cyclic adenosine monophosphate response element-binding proteins (CREB) and their interaction with brain-derived neurotrophic factor (BDNF) are essential elements in signal transduction pathways important for cellular resilience and neuroplasticity. They play a decisive role in the concept of altered neuroplasticity in major depression.
Among Older People, Lessening Social Activity Linked To Decline In Motor Functions Such As Dexterity And Strength
A new study from the US suggests that the less socially active an older person is, the higher the chances that their motor ability such as strength and dexterity will decline. The study was the work of Dr Aron S. Buchman, and colleagues at Rush University Medical Center in Chicago, and is published in the 22 June issue of Archives of Internal Medicine, a JAMA/Archives journal. Reducing motor function is a common feature of old age, characterized by a gradual loss of motor ability ranging from mild reduction in bulk, muscle strength, speed and dexterity, to severe impairment and disability, wrote the authors in their background information.
Cancer the word resonates in people's nightmares and strikes fear in the hearts of millions. Can there be a positive side amidst the panic, anxiety and hopeless feelings that often accompany the word? The answer is yes according to Dr. Patricia Mumby, associate professor Loyola University Chicago Stritch School of Medicine Psychiatry and Behavioral Neurosciences Department and director of Loyola Cardinal Bernadine Cancer Center Psychosocial Oncology Service. "When we first ask people to find something good about having cancer they pause and give us a puzzled look, but a majority of cancer survivors and patients can find positives. The longer it's been since their diagnosis the more positives they can find, " said Mumby.
New research from Washington University School of Medicine in St. Louis has found substantial reductions in binge drinking since the national drinking age was set at 21 two decades ago, with one exception: college students. The rates of binge drinking in male collegians remain unchanged, but the rates in female collegians have increased dramatically. Reporting in the July issue of the Journal of the American Academy of Child and Adolescent Psychiatry, the researchers say although policy initiatives aimed at lowering rates of underage drinking generally have been successful and that binge drinking is down among young people overall, it remains a problem on college campuses.
Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatments For Depression
Clinical Data, Inc. (NASDAQ: CLDA) announced today that the United States Adopted Name Council (USAN) has approved the generic name vilazodone hydrochloride. Vilazodone, if approved, would represent a first-in-class drug for the treatment of depression, due to its novel dual mechanism of action as both a potent and selective serotonin reuptake inhibitor (SSRI) and a partial agonist of the 5-hydroxytryptamine 1a (5-HT1A) receptor. Thus, vilazodone combines first-line therapy for depression with 5-HT1A partial agonism, an accepted adjunctive treatment for depression and a first-line therapy for anxiety disorders. Clinical Data has recently completed the second of two positive Phase III registration studies.
Withdrawal of the painkiller co-proxamol from the UK market has led to a major reduction in suicides and accidental poisonings involving the drug, without an increase in deaths from other painkillers, finds research published on bmj.com today. Co-proxamol was the most commonly prescribed drug used in suicides and was responsible for 766 deaths between 1997 and 1999 in England and Wales. Concerns about large numbers of fatal poisonings led the Committee on Safety in Medicines to announce in 2005 the phasing out of co-proxamol from use in the UK by the end of 2007. Whether this initiative has been effective and reduced poisoning deaths has not been assessed.